Alimentiv Health Trust

What Alimentiv Health Trust does

Alimentiv Health Trust is a specialized gastrointestinal (GI) contract research organization (CRO) providing end-to-end clinical trial services to pharmaceutical and biotechnology sponsors developing therapies for GI indications, with a primary focus on inflammatory bowel disease (IBD). The company, founded in 1986 (formerly Robarts Clinical Trials) and headquartered in London, Ontario, Canada, operates through wholly-owned subsidiaries in the United States, the Netherlands, and Australia, employing approximately 550 staff globally. Alimentiv supports more than 40 global pharma, biotech, and CRO customers, has been involved in more than 70% of IBD compounds in development, and runs trials across 5,000+ specialized GI sites in 60+ countries.

The company's core technology stack is a portfolio of proprietary imaging and central reading platforms: Notō (multimodal imaging platform spanning endoscopy, digital pathology, MRI/MRE, and ultrasound), CIMS and CIMSPlus HD (endoscopy image management), Lucidity (digital pathology central review), and the AI-powered DovaVision UC and PathwaysGI tools that provide automated quality control and frame-level disease scoring for ulcerative colitis endoscopy. Alimentiv has authored industry-defining scoring instruments — including the UC-100 Score, Robarts Histopathology Index, and SIQ-UC/SIQ-CD patient-reported outcomes — supported by 200+ peer-reviewed publications in the last five years and compliance with ISO 27001, GDPR, HIPAA, and FDA 21 CFR Part 11. Its histopathology subsidiary AcelaBio provides laboratory and biomarker services.

Revenue is generated through project-based, quote-priced professional services contracts with enterprise pharma and biotech sponsors, typically structured as multi-year engagements. Go-to-market is direct enterprise sales augmented by scientific presence at major GI conferences (ECCO, DDW, UEGW, ICDS) and strategic partnerships (PhaseV for AI-driven trial optimization, Crohn's & Colitis Foundation for IBD Plexus data integration, IBUS for noninvasive imaging endpoints). The 2021 acquisition of McDougall Scientific extended biostatistics capability. Annual revenue exceeds $40 million CAD per Bill S-211 compliance disclosure, and the company is privately held under Alimentiv Holdings Inc., with the Alimentiv Health Trust anchoring its mission and independence.

Name

Alimentiv Health Trust

Legal name

Alimentiv Inc.

Website

https://alimentiv.com

Company type

Private

Founded year

1986

Operating status

Operating

Headcount range

251–500 employees

Short description

Alimentiv Health Trust is a specialized gastrointestinal CRO providing end-to-end clinical trial services, proprietary medical imaging platforms, and AI-powered endoscopy scoring tools to pharmaceutical and biotech sponsors developing GI therapies across 60+ countries.

Ownership category

akta.pro rank

Product category

Gastroenterology Contract Research Organization (GI CRO) Services

NAICS

Medical and Diagnostic Laboratories (6215), Custom Computer Programming Services (541511), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Liver & GI Clinical Research (Trials Centers) (HLAKAEAL)

akta.pro secondary industries

Data Management, Biostatistics & Statistical Programming FSP (HLAGAOAB), Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines) (HLACAOAO), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Gastroenterology clinical trials
• Medical imaging solutions
• Central reading services
• Clinical research organization
• Digital pathology services

Headquarters

HQ city

London

HQ country

Canada

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: Alimentiv provides end-to-end clinical trial services for gastroenterology studies, including clinical operations, medical imaging solutions, central reading, biostatistics, regulatory strategy, and consulting services. Revenue is generated through project-based contracts with pharma sponsors, biotech companies, and CROs.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Alimentiv is a specialized gastroenterology Contract Research Organization that delivers end-to-end clinical trial services — including trial design, clinical operations, biostatistics, regulatory strategy, medical monitoring, and consulting — combined with proprietary medical imaging and AI-powered tools for endoscopy, histology, and noninvasive imaging endpoints. Its technology stack includes the Notō multimodal imaging platform, CIMS/CIMSPlus HD endoscopy systems, Lucidity digital pathology, and AI tools DovaVision UC and PathwaysGI for automated quality control and frame-level disease scoring. The company supports more than 70% of IBD compounds in development for global pharmaceutical, biotech, and CRO sponsors.

Product overview

Alimentiv is a premier gastrointestinal Contract Research Organization (CRO) offering a unified platform of proprietary imaging and clinical trial technology. The core offering consists of end-to-end clinical trial services combined with a purpose-built medical imaging technology portfolio, including Notō (multimodal imaging platform), CIMS/CIMSPlus HD (endoscopy management), and Lucidity (digital pathology). AI-powered features DovaVision UC and PathwaysGI provide automated quality control and disease scoring. Services span clinical trial design, operations, regulatory strategy, medical imaging, central reading, and consulting, all integrated to deliver standardized, regulator-ready endpoints for GI clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• AcelaBio: State-of-the-art histopathology lab providing end-to-end GI histopathology and precision medicine services
• CIMS
• CIMSPlus HD
• Noto
• Lucidity
• DovaVision UC
• PathwaysGI

Products and services

• Notō multimodal imaging platform Proprietary multimodal imaging platform that standardizes capture and review across endoscopy, digital pathology, MRI/MRE, and ultrasound. It guides sites with study-specific checklists, tracks upload quality in real time, and routes cases to central readers with full audit trails for GI clinical trial sponsors.
• CIMS (Clinical Imaging Management System) for endoscopy Endoscopy image management solution that standardizes endoscopy image capture and secure upload, routes cases to blinded readers, maintains a full audit trail, and delivers regulator-ready results to EDC on schedule for GI clinical trial sponsors.
• CIMSPlus HD endoscopy image management High-definition version of the endoscopy image management system providing enhanced imaging capabilities for standardized endoscopy image capture and secure upload in clinical trials for GI sponsors.
• Lucidity digital pathology central review Digital pathology central review platform for standardized, blinded review of digitized histology slides designed for secure and compliant handling of whole-slide images for GI clinical trial sponsors.
• DovaVision UC AI-powered tool for ulcerative colitis endoscopy that provides automated quality control and granular, frame-level disease scoring, enabling cumulative disease scoring (CDS) for GI clinical trial sponsors.
• PathwaysGI AI-powered precision tool for GI endoscopy providing automated quality control and disease scoring capabilities to accelerate decisions and improve reproducibility for GI clinical trial sponsors.
• GI Clinical Trial Services End-to-end clinical trial services for gastroenterology studies, including clinical development strategy, trial design and protocol development, clinical project management, GI biostatistics, site management and risk-based monitoring, regulatory strategy, medical monitoring, clinical data science, medical writing, and clinical safety for global pharma, biotech, and CRO sponsors.
• Medical Imaging Solutions and Central Reading Blinded central reading by expert GI clinicians for endoscopy, histology, intestinal ultrasound, and MRI/MRE, supported by validated scoring methods and structured workflows that minimize variability and reduce bias, combined with the Notō, CIMS, Lucidity, DovaVision UC, and PathwaysGI technology platforms.
• Laboratory and Biomarker Services GI histopathology and precision medicine laboratory services delivered through the AcelaBio subsidiary, providing end-to-end tissue and biomarker analysis for gastroenterology clinical trial sponsors.
• GI Clinical Trial Consulting Services Specialized GI clinical research consulting including statistical consulting and management, scientific advisory, and trial design support for pharmaceutical, biotechnology, and CRO clients.

Quantifiable outcome

• Supported >70% of IBD compounds in development
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• PhaseVcoreStrategic or Co-development Partner · 22 January 2026PhaseV partnered with Alimentiv as part of its strategic partnerships with the Crohn's & Colitis Foundation and Alimentiv to expand its AI-driven ClinOps Optimizer platform for IBD clinical trials. PhaseV presented study results at the 2026 Crohn's & Colitis Congress demonstrating how its AI/ML platform improves inflammatory bowel disease clinical trial efficiency through causal machine learning and real-time analytics.
• IBUScoreStrategic or Co-development PartnerStrategic partnership with IBUS for standardized protocols and central reading of intestinal ultrasound (IUS) and magnetic resonance enterography (MRE/MRI). This partnership enables patient-centric endpoints without invasive procedures, improving patient experience and trial efficiency.
• Crohn's & Colitis FoundationcoreStrategic or Co-development PartnerPartnership integrating data from the Crohn's & Colitis Foundation's IBD Plexus® to optimize site selection and trial execution. The collaboration supports PhaseV's platform which leverages this data for AI-driven clinical trial optimization in IBD.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medpace: Therapeutic-focused mid-size CRO with a specialty clinical development model analogous to Alimentiv's GI focus; comparable in size, scientific orientation, and dedicated therapeutic expertise model.
• Veristat: Specialty biostatistics and clinical development CRO closely analogous to Alimentiv's statistics and regulatory services; serves biotech sponsors with similar project-based model.
• Worldwide Clinical Trials: Mid-size specialty CRO with therapeutic area expertise; comparable in size and positioning as a focused alternative to large generalist CROs.
• Clario: Clinical trial technology and imaging core lab provider offering centralized reading, image management, and endpoint solutions for clinical trials; directly comparable to Alimentiv's CIMS, Notō, and Lucidity offerings.
• Cytel: Specialty biostatistics, statistical programming, and clinical data science provider with a scientific leadership model similar to Alimentiv's GI biostatistics practice.

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Large full-service CRO spun out from Labcorp; provides clinical operations, central laboratory, and imaging services overlapping with Alimentiv's offering for global pharma sponsors.
• Parexel International: Global full-service CRO with broad therapeutic-area coverage and significant biotech sponsor relationships; relevant competitor for outsourced GI clinical trial services.
• ICON plc: One of the largest global CROs offering full-service clinical development including gastroenterology and central imaging capabilities; competes for the same pharma/biotech sponsors but across all therapeutic areas.
• Charles River Laboratories: Major CRO/CDMO with discovery, preclinical, and clinical services; serves overlapping pharma/biotech client base and increasingly competes in specialty clinical trial delivery.
• IQVIA: World's largest CRO with broad therapeutic-area coverage and proprietary technology platforms; competes for the same enterprise pharma/biotech clients and overlapping GI trial work.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/alimentiv
• YouTubeyoutube.com/@alimentiv8700
• LinkedInlinkedin.com/company/alimentiv
• Facebookfacebook.com/Alimentiv

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alimentiv Health Trust